bbo-11818
Generic: KRAS Mutant Inhibitor BBO-11818·Code: BBO-11818
bbo-11818: 1 clinical trial tracked.
bbo-11818 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about bbo-11818, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (1)
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers
Primary endpoint: Incidence and severity of treatment emergent adverse events (TEAEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs)
Interventionalopen665 targetStarted 2025-03Completion 2029-0917 sites · Australia, United StatesTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)